Πέμπτη 5 Νοεμβρίου 2020

Cancers, Vol. 12, Pages 3271: Breast Cancer Heterogeneity and Response to Novel Therapeutics

Alexandros G.Sfakianakis shared this article with you from Inoreader
Μέσω Cancers

cancers-12-03271-ag-550.jpg

Cancers, Vol. 12, Pages 3271: Breast Cancer Heterogeneity and Response to Novel Therapeutics

Cancers doi: 10.3390/cancers12113271

Authors: Mariona Baliu-Piqué Atanasio Pandiella Alberto Ocana

Targeted cancer therapies against oncogenic drivers are actively being developed and tested in clinical trials. Targeting an oncogenic driver may only prove effective if the mutation is present in most tumoral cells. Therefore, highly heterogeneous tumors may be refractory to these therapies. This makes tumor heterogeneity a major challenge in cancer therapy. Although heterogeneity has traditionally been attributed to genetic diversity within cancer cell populations, it is now widely recognized that human cancers are heterogeneous in almost all distinguishable phenotypic characteristics. Understanding the genetic variability and also the non-genetic influences of tumor heterogeneity will provide novel insights into how to reverse therapeutic resistance and improve cancer therapy.

View on the web

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.